PanCO: Updated results of an open-label, single-arm pilot study of OncoSil P-32 microparticles in unresectable locally advanced pancreatic adenocarcinoma (LAPC) with gemcitabine plus nab-paclitaxel or FOLFIRINOX chemotherapy

Conference Proceedings

P Ross, A Hendlisz, T Ajithkumar, C Iwuji, M Harris, D Croagh, M Aghmesheh, A Nagrial, N Nguyen, M Nikfarjam, N Wilson, D Kenny, D Turner, H Wasan

ANNALS OF ONCOLOGY | ELSEVIER | Published : 2020

OncoSil Medical Ltd., Sydney, Australia.